Canaccord Genuity Maintains a 'Buy' on NuVasive (NUVA); Q2 Review
Get Alerts NUVA Hot Sheet
Price: $39.75 --0%
Rating Summary:
11 Buy, 21 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Rating Summary:
11 Buy, 21 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on NuVasive (NASDAQ: NUVA) price target of $27.00.
Analyst, William J. Plovanic, said, "We maintain our rating on NuVasive following Q2/12 results. We note that while non-GAAP earnings outperformed relative to our and consensus expectations, revenue results were somewhat disappointing, (despite being in line). Specifically, given the strong Q1/12 and our expectations for a continued rebound in the US metal business, Q2/12 results were driven by OUS and US biologics, and not metal. That said, management increased 2012 guidance on the
top and bottom lines and multiple new products are expected to drive H2/12 and 2013 growth."
For an analyst ratings summary and ratings history on NuVasive click here. For more ratings news on NuVasive click here.
Shares of NuVasive closed at $22.92 yesterday.
Analyst, William J. Plovanic, said, "We maintain our rating on NuVasive following Q2/12 results. We note that while non-GAAP earnings outperformed relative to our and consensus expectations, revenue results were somewhat disappointing, (despite being in line). Specifically, given the strong Q1/12 and our expectations for a continued rebound in the US metal business, Q2/12 results were driven by OUS and US biologics, and not metal. That said, management increased 2012 guidance on the
top and bottom lines and multiple new products are expected to drive H2/12 and 2013 growth."
For an analyst ratings summary and ratings history on NuVasive click here. For more ratings news on NuVasive click here.
Shares of NuVasive closed at $22.92 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Moncler SpA (MONC:IM) (MONRY) PT Raised to EUR69 at RBC Capital
- Lam Research (LRCX) PT Raised to $1,130 at B.Riley
- Old Republic (ORI) Tops Q1 EPS by 2c
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Earnings, Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!